CB1 cannabinoid receptors are involved in neuroprotection via NF-κB inhibition

Journal of Cerebral Blood Flow and Metabolism

Volumn 25, Issue 4, 2005, Pages 477-484

  Panikashvili, David ^a   Mechoulam, Raphael ^a   Beni, Sara M ^a   Alexandrovich, Alexander ^a   Shohami, Esther ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cannabinoid receptors; Endocannabinoids; Inflammation; Neuroprotection; NF B; Traumatic brain injury

Indexed keywords

2 ARACHIDONOYLGLYCEROL; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RIMONABANT; 2-ARACHIDONYLGLYCEROL; ACYLGLYCEROL; ARACHIDONIC ACID DERIVATIVE; DNA; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EDEMA; BRAIN INFARCTION SIZE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; EDEMA; HEAD INJURY; INFLAMMATION; KNOCKOUT MOUSE; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; WILD TYPE; ANIMAL; ANIMAL BEHAVIOR; BRAIN INFARCTION; BRAIN LEVEL; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; GEL MOBILITY SHIFT ASSAY; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ARACHIDONIC ACIDS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; BRAIN EDEMA; CEREBRAL INFARCTION; DNA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GLYCERIDES; HEAD INJURIES, CLOSED; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPROTECTIVE AGENTS; NF-KAPPA B; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION;

EID: 17044364809     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jcbfm.9600047     Document Type: Article

References (46)

1. Baeuerle PA, Henkel T (1994) Function and activation of NF-kappa B in the immune system. Ann Re Immuno 12:141-79
2. Beni-Adani L, Gozes I, Cohen Y, Assaf Y, Steingart RA, Brenneman DE, Eizenberg O, Trembolver V, Shohami E (2001) Reduced mortality and improved recovery after treatment with a femtomolar-acting peptide in a mouse model of closed head injury. J Pharmacol Exp Ther 296:57-63
3. Beni SM, Kohen R, Reiter RJ, Tan DX, Shohami E (2004) Melatonin-induced neuroprotection after closed head injury is associated with increased brain antioxidants and attenuated late-phase activation of NF-kappaB and AP-1. FASEB J 18:149-51
4. Cernak I, Vink R, Natale J, Stoica B, Lea 4th PM, Movsesyan V, Ahmed F, Knoblach SM, Fricke ST, Faden AI (2004) The 'dark side' of endocannabinoids: a neurotoxic role for anandamide. J Cereb Blood Flow Metab 24:564-78
5. Chen Y, Constantini S, Trembovler V, Weinstock M, Shohami E (1996) An experimental model of closed head injury in mice: pathophysiology, histopathology, and cognitive deficits. J Neurotrauma 13:557-68
6. 2 cannabinoid receptors are implicated in inflammatory pain. Pain 96:253-60
7. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-5
8. Fride E, Ginzburg Y, Breuer A, Bisogno T, Di Marzo V, Mechoulam R (2001) Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol 419:207-14
9. Gallily R, Breuer A, Mechoulam R (2000) 2-Arachidonyl-glycerol, an endogenous cannabinoid, inhibits tumor necrosis factor α-production in murine macrophages, and in mice. Eur J Pharmacol 406:R5-R7
10. Grundy RI, Rabuffetti M, Beltramo, M (2001) Cannabinoids and neuroprotection. Mol Neurobiol 24:29-51
11. Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95:8268-73
12. Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I, Berrendero F, Manzanares J, Ikonomidou C, Schmid HH, Fernandez-Ruiz JJ, Hansen HS (2001) Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem 78:1415-27
13. Hansen HS, Moesgaard B, Petersen G, Hansen HH (2002) Putative neuroprotective actions of N-acyl-ethanolamines. Pharmacol Ther 95:119-26
14. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Fride E (1999) HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96:14228-33
15. Herring AC, Kaminski NE (1999) Cannabinol-mediated inhibition of nuclear factor-kappaB, cAMP response element-binding protein, and interleukin-2 secretion by activated thymocytes. J Pharmacol Exp Ther 291:1156-63
16. Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18:621-63
17. Knoller N, Levi L, Shoshan I, Reichenthal E, Razon N, Rappaport ZH, Biegon A (2002) Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit Care Med 30:548-54
18. Lewen A, Matz P, Chan PH (2000) Free radical pathways in CNS injury. J Neurotrauma 17:871-90
19. Malek S, Chen Y, Huxford T, Ghosh G (2001) IκBβ but not IκBα functions as a classical cytoplasmic inhibitor of NF-κB dimers by masking both NF-κB nuclear localization sequences in resting cells. J Biol Chem 276:45225-35
20. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffine G, Bayewitch M, Barg J, Vogel Z (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90
21. Mechoulam R (2002) Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostagland Leukotr Essent Fatty Acids 66:93-9
22. Mechoulam R, Spatz M, Shohami E (2002) Endocannabinoids and neuroprotection. Sci STKE, http:// www.stke.org/cgi/content/full/ OC_sigtrans;2002/129/re5
23. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19:2987-95
24. Ouyang Y, Hwang SG, Han SH, Kaminski NE (1998) Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells. Mol Pharmacol 53:676-83
25. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413:527-31
26. Paria BC, Song H, Wang X, Schmid PC, Krebsbach RJ, Schmid HH, Bonner TI, Zimmer A, Dey SK (2001) Dysregulated cannabinoid signaling disrupts uterine receptivity for embryo implantation. J Biol Chem 276:20523-8
27. 1 cannabinoid receptor knock-out mice. J Neurosci 22:9771-5
28. Perkins ND (2000) The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci 25:434-40
29. Shen M, Thayer SA (1998) Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 54:459-62
30. Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T (1997) Cytokine production in the brain following-closed head injury: dexanabinol (HU-211) is a novel TNF inhibitor and an effective neuroprotectant. J Neuroimmunol 72:169-77
31. Shohami E, Mechoulam R (2000) Dexanabinol (HU-211): a nonpsychotropic cannabinoid with neuroprotective properties. Drug Dev Res 50:211-5
32. Sinor AD, Irvin SM, Greenberg DA (2000) Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett 278:157-60
33. Sofia RD, Knobloch LC, Vassar HB (1973a) The anti-edema activity of various naturally occurring cannabinoids. Res Commun Chem Pathol Pharmacol 6:909-18
34. 9-tetrahydrocannabinol (THC). J Pharmacol Exp Therap 186:646-55
35. Sofia RD, Nalepa SD, Vassar HB, Knobloch LC (1974) Comparative anti-phlogistic activity of delta 9-tetrahydrocannabinol, hydrocortisone and aspirin in various rat paw edema models. Life Sci 15:251-60
36. 1 cannabinoid receptor knockout mice. Proc Natl Acad Sci USA 96:5786-90
37. Stover JF, Schoning B, Beyer TF, Woiciechowsky C, Unterberg AW (2000) Temporal profile of cerebrospinal fluid glutamate, interleukin-6, and tumor necrosis factor-alpha in relation to brain edema and contusion following controlled cortical impact injury in rats. Neurosci Lett 288:25-8
38. Sugiura T, Yoshinaga N, Kondo S, Waku K, Ishima Y (2000) Generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in picrotoxinin-administered rat brain. Biochem Biophys Res Commun 271:654-8
39. Tam WF, Sen R (2001) IκB family members function by different mechanisms. J Biol Chem 276:7701-4
40. van der Stelt M, Veldhuis WB, Bar PR, Veldink GA, Vliegenthart JF, Nicolay K (2001a) Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. Neurosci 21:6475-9
41. van der Stelt M, Veldhuis WB, Van Haaften GW, Fezza F, Bisogno T, Bar PR, Veldink GA, Vliegenthart JF, Di Marzo V, Nicolay K (2001b) Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neuroscience 21:8765-71
42. van der Stelt M, Veldhuis WB, Maccarrone M, Bar PR, Nicolay K, Veldink GA, Di Marzo V, Vliegenthart JF (2002) Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 26:317-46
43. Vollgraf U, Wegner M, Richter-Landsberg C (1999) Activation of AP-1 and nuclear factor-kappa B transcription factors is involved in hydrogen peroxide-induced apoptotic cell death of oligodendrocytes. J Neurochem 73:2501-9
44. Yatsiv I, Morganti-Kossmann MC, Perez D, Dinarello CA, Novick D, Rubinstein M, Otto VI, Rancan M, Kossmann T, Redaelli CA, Trentz O, Shohami E, Stahel PF (2002) Elevated intracranial IL-18 in humans and mice after traumatic brain injury and evidence of neuroprotective effects of IL-18-binding protein after experimental closed head injury. J Cereb Blood Flow Metab 22:971-8
45. 1 receptor knockout mice. Proc Natl Acad Sci USA 96:5780-5
46. Zingarelli B, Sheehan M, Wong HR (2003) Nuclear factor-κB as a therapeutic target in critical care medicine. Crit Care Med 31:S105-S11